Xinjun Liang

机构：Hubei Provincial Center for Disease Control and Prevention, Center for Cancer Research, Hubei Cancer Hospital, Huazhong University of Science and Technology · ORCID：0000-0002-5180-7926

发表论文 86 篇 · 总被引 1113 次 · h-index 17

代表论文

• A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors (2025 · Clinical Cancer Research · 被引 17)
• Preliminary result of a phase Ib study: Efficacy and safety of FG-M108 plus gemcitabine and nab-paclitaxel in patients with Claudin18.2-positive, locally advanced, unresectable, or metastatic pancreatic cancer. (2025 · Journal of Clinical Oncology · 被引 2)
• Abstract LB212: Efficacy and safety of JS015 (an anti-dickkopf-1 antibody) in combination with standard of care in patients with gastrointestinal cancers (2025 · Cancer Research · 被引 1)
• Preliminary result of a phase Ib study: Efficacy and safety of FG-M108 plus gemcitabine/nab-paclitaxel as first-line (1L) treatment in patients with Claudin18.2-positive locally advanced unresectable or metastatic (LA/m) pancreatic cancer. (2025 · Journal of Clinical Oncology · 被引 1)
• Molecular studies on the impact of microbiome on anticancer drug resistance (2026 · Frontiers in Immunology)
• Immunotherapy Resistance in dMMR/MSI‐H Colorectal Cancer: Unraveling Mechanisms and Exploring Overcoming Strategies (2026 · Journal of Immunology Research)